Effectiveness and Safety of the drug Remogliflozin in diabetic patients with fat accumulation in liver
Phase 3
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2020/02/023250
- Lead Sponsor
- Kshirsagar Shivani Prakash
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Controlled Type 2 Diabetes Mellitus on Metformin therapy
Diagnosed with Non-Alcoholic Fatty liver disease
Fasting plasma glucose less than than 250 mg/dl
Willing to participate in the study and comply with it procedures by signing a written informed consent
Exclusion Criteria
age less than 18 years and more than 75 years
Uncontrolled Diabetes Mellitus
Diabetic patients on Insulin therapy
Fasting plasma glucose more than 250 mg/dl
Viral Hepatitis
Autoimmune Hepatitis
Primary Billiary Cirrhosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method